No. | Publication Date | Citing Article |
---|---|---|
1 | 2023 | Yang Xing, Feroza Yasinjan, Yajie Du, Huayue Geng, Ying Zhang, Minghua He, Rui Guo, Lei Yang, Jiayue Cui, Dongmei Mu, Ziling Liu, Hong Wang. Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials, Frontiers in Immunology. 2023; 14: 1094437. https://doi.org/10.3389/fimmu.2023.1094437 |
2 | 2023 | Chukwunonso K. Nwabufo, Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations, Cancer Chemotherapy and Pharmacology. 2023; https://doi.org/10.1007/s00280-023-04575-y |
3 | 2023 | Rebecca L. Porter, Ursula A. Matulonis. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer, Expert Review of Anticancer Therapy. 2023; 23: 783. https://doi.org/10.1080/14737140.2023.2236793 |